Valens GroWorks Corp (CSE : VGW)

IF YOU ENJOY OUR WEBSITE, JOIN OUR FACEBOOK GROUP AND GET NOTIFIED FIRST. CLICK HERE.

Image result for valens groworks

Valens GroWorks Corp. is a research-driven, Canadian cannabis company focused on downstream secondary extraction methodology, distillation and cannabinoid isolation and purification.

Our mission is to become the world’s most trusted partner for best-in-class cannabis extraction, testing, formulations and product development.

Key highlights:

  • Valens Labs obtained ISO 17025 accreditation for cannabis testing, to give producers certainty that they are producing high-quality, safe products

What’s ISO 17025

ISO/IEC 17025 General requirements for the competence of testing and calibration laboratories is the main ISO standard used by testing and calibration laboratories. In most countries, ISO/IEC 17025 is the standard for which most labs must hold accreditation in order to be deemed technically competent.

  • increase of its annual extraction capacity of dried cannabis and hemp to 240,000KG
  • entered into multiple extraction service agreements with BIG and SMALL LPs including #Canopy Growth #Tilray #HEXO #TGOD #Organigram #Sundial #Speakeasy, #Harvest One and #GTEC
  • Named a “Center of Excellence in Plant Based Science” by Thermo Fisher Scientific.

COMPETITIVE LANDSCAPE

*Yahoo finance dated 26 / 04 /2019

* Sources from company presentation & news releases

HOW VALENS GENERATE HIGH MARGINS

SORSE EMULSION TECHNOLOGY:

<Zero Cannabis Taste, Color & Odor that observed in 5 – 15 minutes>

Q1 2019 Financial Results

  • Revenue increased to $2,220,200 for the first quarter of 2019 compared with $nil in the same period in fiscal 2018.
  • Gross profit increased to $850,525, or 38.3% of revenue, for the first quarter of 2019 compared with $nil in the same period in fiscal 2018.
  • Strong balance sheet with $20,552,286 in cash and short-term investments and a net working capital position of $26,391,610 as at February 28, 2019.
Image result for cannabis extraction

Key Message from CEO:

Tyler Robson, CEO of Valens, quoted, “The first quarter of 2019 was a key inflection point for Valens as we accelerated our ramp up into commercial production, generating revenues of $2.2 million compared with $nil in the same period of fiscal 2018.

This initial momentum was driven by contracts signed late in 2018 to provide cannabis extraction services to leading licensed producers, including Canopy Growth and Harvest One.

The growth in the size and frequency of shipments from these contracts increased throughout the quarter and into the second quarter of fiscal 2019, while at the same time Valens also secured a number of new, large scale contracts with other leading licensed producers including with Organigram, Tilray, and The Green Organic Dutchman.

2018 progress:

  • Extraction capacity expansion
  • 8 public multi-year extraction agreements
  • Partnership with thermo fisher scientific
  • ISO 17025 valens labs accreditation
  • Standard processing, cultivation and analytical testing licenses
  • Global partnerships for supply & Distribution
  • raised $41 million in capital

2019 FOCUS

Analysts Target Price :

  • GMP : $10.00
  • Mackie Research : $6.75
  • Haywood : $5.25

Sources

  • April 2019 Investor Presentation
  • https://midasletter.com/2019/04/valens-groworks-corp-cnsxvgw-delivers-q1-2019-earnings-q2-processing-run-rate-sizzles-2/
  • https://investingnews.com/daily/cannabis-investing/haywood-capital-markets-provides-coverage-on-valens/
  • https://www.proactiveinvestors.co.uk/companies/news/219135/mackie-boosts-price-target-on-valens-groworks-to-c675-after-stellar-1q-financials-219135.html
  • https://gmpsecurities.bluematrix.com/sellside/EmailDocViewer?encrypt=ebf642fe-10e1-4240-95be 688a1cdbdb5b&mime=HTML&co=Gmpsecurities&id=noauthentication@bluematrix.com&source=libraryView
  • https://www.valensgroworks.com/press-releases/valens-signs-multi-year-cannabis-and-hemp-extraction-agreement-with-hexo-corp/

Author: Yong Sok Leng

Disclaimer: All posts made on this website are provided for information purposes only. None of the information here is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. Before making an investment decision, you should seek the advice of a qualified and registered securities professional. The Author is not paid to share this content and may or may not own shares in the company.

Advertisements

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.